ERBB2 and gastric cancer: In order to investigate the role of HER2 in mediating EMT in cisplatin-resistant gastric cancer cells, we utilized multiple strategies, including monoclonal antibody Herceptin blocking method, siRNA technique, and small molecular targeted therapeutic drug CP724714 treatment.